Kymera Therapeutics Income Statement (2019-2025) | KYMR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.95M1.83M3.43M3.29M14.53M12.79M18.70M18.52M20.34M15.28M9.62M11.51M9.55M16.14M9.47M16.51M4.73M47.88M10.29M25.65M3.74M-36.58M22.10M11.48M2.76M
Operating items
Research & Development 11.31M11.09M12.12M13.82M15.78M20.39M25.96M35.22M38.31M37.53M35.94M41.29M43.88M43.13M42.23M45.77M48.12M52.97M48.82M59.20M60.41M71.82M80.25M78.39M74.09M
Selling, General & Administrative 1.50M2.53M2.56M3.66M6.84M5.17M5.91M8.03M10.67M11.74M10.61M11.03M10.56M11.64M12.56M14.13M14.12M14.23M14.37M17.37M15.46M16.33M16.27M17.64M17.34M
Other Operating Expenses 4.92M3.85M
Operating Expenses 12.81M13.62M14.68M17.48M22.62M25.57M31.87M43.25M48.97M49.27M46.55M52.32M54.43M54.77M54.79M59.90M62.24M67.20M68.12M76.58M75.86M88.15M96.53M96.03M95.28M
Operating Income -11.86M-11.78M-11.25M-14.19M-8.08M-12.78M-13.17M-24.73M-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M
EBIT -11.86M-11.78M-11.25M-14.19M-8.08M-12.78M-13.17M-24.73M-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M
Non-operating items
Other Non Operating Income 0.45M0.30M0.35M0.23M0.12M0.12M0.12M0.10M0.12M0.14M0.29M0.59M1.92M3.82M4.45M4.63M4.68M5.00M9.34M8.92M9.70M10.06M8.92M8.05M10.44M
Non Operating Income 0.44M0.27M0.32M0.20M0.10M0.10M0.09M0.07M0.06M0.09M0.25M0.55M1.88M3.77M4.40M4.58M4.64M4.94M9.27M8.86M9.64M10.00M8.85M7.94M10.35M
Net income details
EBT -11.87M-11.81M-11.28M-14.22M-8.11M-12.81M-13.19M-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M
Profit After Tax -11.42M-11.51M-10.93M-13.99M-7.99M-12.69M-13.07M-24.66M-28.58M-33.90M-36.68M-40.26M-43.00M-34.87M-40.93M-38.80M-52.87M-14.37M-48.56M-42.06M-62.49M-70.75M-65.58M-76.61M-82.17M
Income from Continuing Operations -11.87M-11.81M-11.28M-14.22M-8.11M-12.81M-13.19M-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M
Consolidated Net Income -11.87M-11.81M-11.28M-14.22M-8.11M-12.81M-13.19M-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M
Income towards Parent Company -11.87M-11.81M-11.28M-14.22M-8.11M-12.81M-13.19M-24.76M-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M
Preferred Dividend Payments 9.05M
Net Income towards Common Stockholders -11.42M-11.51M-19.98M-13.99M-7.99M-12.69M-13.07M-24.66M-28.71M-34.05M-36.97M-36.68M-43.00M-34.87M-40.93M-38.80M-52.87M-14.37M-48.56M-42.06M-62.49M-70.75M-65.58M-76.61M-82.17M
Additional items
EPS (Basic) -6.54-6.13-10.23-6.98-0.391.96-0.29-0.55-0.56-0.67-0.71-0.78-0.79-0.59-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.89-0.82-0.95-0.94
EPS (Weighted Average and Diluted) -0.73-0.29-0.56-0.67-0.71-0.78-0.79-0.59-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.89-0.82-0.95-0.94
Shares Outstanding (Weighted Average) 41.72M41.72M41.72M44.46M44.46M45.03M45.03M51.04M51.39M51.70M51.72M51.86M55.18M55.31M55.41M55.49M61.11M61.36M61.75M64.77M64.94M65.12M65.12M71.50M
Shares Outstanding (Diluted Average) 17.35M45.09M50.71M47.99M51.65M51.77M54.54M53.93M58.19M58.33M58.42M58.37M70.77M73.06M76.13M75.04M80.15M80.45M87.30M
EBITDA -11.42M-11.51M-10.72M-14.18M-8.18M-12.65M-12.96M-24.65M-28.73M-34.41M-39.24M-41.02M-44.93M-33.90M-39.02M-39.40M-51.68M-12.47M-49.78M-42.38M-58.46M-74.17M-64.15M-76.28M-80.95M
Interest Expenses 0.00M0.03M0.03M0.03M0.03M0.03M0.02M0.03M0.07M0.05M0.04M0.04M0.04M0.06M0.06M0.05M0.04M0.05M0.07M0.06M0.06M0.06M0.07M0.11M0.10M